The National Cell Repository for Alzheimer's Disease (NCRAD) plays a key role in the National Institute on Aging's (NIA) efforts to identify those at risk for Alzheimer disease (AD) and develop improved treatments to delay or prevent disease onset. NCRAD was established as a cooperative agreement with the NIA to serve as the biospecimen core for all NIA-funded dementia studies. Under the advisement of NIA and the NCRAD Executive Committee (NEC), it is the mission of NCRAD to remove critical barriers hindering research progress to understand the etiology of dementia. To achieve this goal, NCRAD has two primary functions: sample banking and sample distribution. This application is in response to a request by NIA to continue the support for NCRAD (PAR-15-316). NCRAD will work closely with other national efforts in AD research to achieve the following specific aims:
Aim 1 : To provide a state-of-the-art central biospecimen repository for all NIA-funded dementia studies.
Aim 2 : To facilitate and foster sample sharing to all qualified investigators.

Public Health Relevance

This application proposes to renewal the National Cell Repository for Alzheimer Disease (NCRAD), an NIA funded repository for dementia-related studies. NCRAD will work closely with NIA, studies banking samples, as well as researchers requesting samples to ensure that the biospecimens banked at NCRAD are of the highest quality. These biospecimens will be used to perform research with the ultimate goal of developing new treatments for Alzheimer disease and other types of dementia.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Silverberg, Nina B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Indiana University-Purdue University at Indianapolis
Schools of Medicine
United States
Zip Code
Girdhar, Kiran; Hoffman, Gabriel E; Jiang, Yan et al. (2018) Cell-specific histone modification maps in the human frontal lobe link schizophrenia risk to the neuronal epigenome. Nat Neurosci 21:1126-1136
Kunutsor, Setor K; Laukkanen, Jari A; Burgess, Stephen (2018) Genetically elevated gamma-glutamyltransferase and Alzheimer's disease. Exp Gerontol 106:61-66
Nordestgaard, Liv Tybjærg; Tybjærg-Hansen, Anne; Rasmussen, Katrine Laura et al. (2018) Genetic variation in clusterin and risk of dementia and ischemic vascular disease in the general population: cohort studies and meta-analyses of 362,338 individuals. BMC Med 16:39
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Lee, Younghee; Han, Seonggyun; Kim, Dongwook et al. (2018) Genetic variation affecting exon skipping contributes to brain structural atrophy in Alzheimer's disease. AMIA Jt Summits Transl Sci Proc 2017:124-131
DeMichele-Sweet, M A A; Weamer, E A; Klei, L et al. (2018) Genetic risk for schizophrenia and psychosis in Alzheimer disease. Mol Psychiatry 23:963-972
Blue, Elizabeth E; Bis, Joshua C; Dorschner, Michael O et al. (2018) Genetic Variation in Genes Underlying Diverse Dementias May Explain a Small Proportion of Cases in the Alzheimer's Disease Sequencing Project. Dement Geriatr Cogn Disord 45:1-17
Deutschländer, Angela B; Boeve, Bradley F; Rosen, Howard J et al. (2018) Tau Mutations as a Novel Risk Factor for Cancer-Letter. Cancer Res 78:6523-6524
Staffaroni, Adam M; Brown, Jesse A; Casaletto, Kaitlin B et al. (2018) The Longitudinal Trajectory of Default Mode Network Connectivity in Healthy Older Adults Varies As a Function of Age and Is Associated with Changes in Episodic Memory and Processing Speed. J Neurosci 38:2809-2817
Blue, E E; Yu, C-E; Thornton, T A et al. (2018) Variants regulating ZBTB4 are associated with age-at-onset of Alzheimer's disease. Genes Brain Behav 17:e12429

Showing the most recent 10 out of 422 publications